SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 6, 2002
--------------------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
-------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-18231 84-1043826
---------------------------- --------------------- ---------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
2579 Midpoint Drive, Fort Collins, Colorado 80525
-------------------------------------------------
(Address of principal executive offices, including zip code)
(970) 482-5868
---------------------------------------------------
(Registrant's telephone number, including area code)
Item 5. Other Events.
The Registrant is filing this Report to amend Exhibits 10.1, 10.2
and 10.3 for which confidential treatment is being sought, and which exhibits
were originally filed in its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2001 as filed with the Securities and Exchange Commission on
October 30, 2001.
Item 7. Exhibits.
10.01* Eighth Amendment to Agreement by and between Atrix
Laboratories, Inc. and Block Drug Corporation, dated as of
August 24, 2001.
10.02* License Agreement by and between Atrix Laboratories, Inc. and
CollaGenex Pharmaceuticals, Inc., dated as of August 24, 2001.
10.03* Stock Purchase Agreement by and between Atrix Laboratories,
Inc. and CollaGenex Pharmaceuticals, Inc., dated as of August
24, 2001.
---------------------
*Confidential treatment has been requested for a portion of these exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ Brian G. Richmond
------------------------
Brian G. Richmond
Chief Financial Officer
Date: March 6, 2002
EXHIBIT INDEX
Exhibit Description
------- -----------
10.01* Eighth Amendment to Agreement by and between Atrix
Laboratories, Inc. and Block Drug Corporation, dated as of
August 24, 2001.
10.02* License Agreement by and between Atrix Laboratories, Inc. and
CollaGenex Pharmaceuticals, Inc., dated as of August 24, 2001.
10.03* Stock Purchase Agreement by and between Atrix Laboratories,
Inc. and CollaGenex Pharmaceuticals, Inc., dated as of August
24, 2001.
------------------
* Confidential treatment has been requested for a portion of these exhibits.